BioSpace News Archive

Instead of detecting the virus, this device can help determine who might be at risk for intubation and mechanical ventilation.

Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.

Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 4, 2020.

Accent Therapeutics and AstraZeneca forged a collaboration valued at about $1.1 billion to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins for the treatment of cancer.

Questions continue to arise around a small company called Surgisphere and the data it collected that was used to form the results in two large COVID-19 studies, including one major study involving the use of the antimalarial drug hydroxychloroquine. Investigations are likely imminent as concerns over the data increase.

The $7.4 billion raised would fund Gavi’s immunization programs between 2021 and 2025, which would help immunize 300 million children and potentially save 7 to 8 million lives.

The fund, called the Emergency Support Instrument, would be used to increase vaccine manufacturing capacity in Europe.

If employers genuinely want to ensure that their workers spend their valuable time on the clock working diligently, then they should consider implementing some of these productivity monitoring programs.

The company plans to use the money to advance its lead candidate, NDX-1017, into Phase II/III clinical trials.